Cell and Organ Transplantology. 2015; 3(1): 57-61.
Effects of the neurogenic cells supernatant on the tumor-inducing ability of glioma 101.8 in rats
Lyubich L. D., Lisyany M. I.
A. P. Romodanov State Institute of Neurosurgery National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
The use of neurogenic stem cells (NSCs) and neurogenic progenitor cells (NPCs) is one of the areas of brain and spinal cord lesions cell therapy. Intensive research of NSCs biology has revealed their tumor-tropic properties. Great migration potential and integration of NSCs in places of pathology in the central nervous system allows to consider their application as a means of targeted therapy of tumors. Antitumor properties of NSCs substantiate the development of treatment strategies for malignant gliomas using NSCs.
The aim was to study the effect of rat neurogenic cells supernatant (NCS) on the tumor-inducing ability of glioma 101.8 cells at the intracerebral implantation in rats.
Brain glioma 101.8 was modeling by intracerebral injection of 101.8-glioma cells suspension. NCS was received from whole rat brain tissue on 14th (E14) day of gestation.
Modification of 101.8-glioma cells suspension by means of incubation with NCS (0.02 and 0.1 mg/ml) reduced the tumor-inducing ability of tumor cells, postponing the time of tumor clinical manifestations debut and increasing the lifetime of experimental animals.
Under conditions of glioma induction with tumor cells, previously modified by NCS, cytotoxic activity of immune cells of tumor-bearing animals in MTT-test with allogeneic 101.8-glioma cells was increased.
Keywords: glioma 101.8; neurogenic progenitor cells supernatant; cytotoxic activity of lymphocytesFull Text PDF
|1. Achanta P, Sedora Roman NI, Qui-ones-Hinojosa A. Gliomagenesis and the use of neural stem cells in brain tumor treatment. Anticancer Agents Med. Chem. 2010; 10(2):121–130.
|2. Kim SU. Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev. 2011; 7(1):130–140.
|3. Ahmed AU, Ulasov IV, Mercer RW, et al. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol. Biol. 2012; 797:97–109.
|4. Khosh N, Brown CE, Aboody KS, et al. Contact and encirclement of glioma cells in vitro is an intrinsic behavior of a clonal human neural stem cell line. PLOS ONE. 2012; 7(12): e51859.-Available: http://www.jourlib.org/paper/3003453|
|5. Aboody KS, Najbauer J, Metz MZ, et al. Neural Stem Cell–Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies. Sci. Transl. Med. 2013; 5(184):184–189.
|6. Bovenberg MS. Advances in stem cell therapy against gliomas. Trends Mol. Med. 2013; 19(5):281–291.
|7. Morshed RA, Gutova M, Juliano J, et al. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Therapy. 2015; 22:55–61.
|8. Shah Kh. Stem cell therapeutics for cancer. Wiley Blackwell, 2013. 304 p.
|9. Hamerlik P. Cancer stem cells and glioblastoma In: Glioma cell biology. Sedo A, Mentlein R. (ed.). Wien: Springer-Verlag. 2014:3–22.
|10. Nakada M, .Kita D, Furuta T, et al. Signalling cascades driving the malignant phenotype of glioma cells. In: Glioma cell biology. Sedo A., Mentlein R. (ed.). Wien: Springer-Verlag. 2014:47–76.|
|11. Halansky AS, Kondakova LI, Avtsyn AP. Novye perevivaemye gliomy golovnogo mozga krys [New transplantable rat brain glioma]. Voprosy nejrohirurgii – Questions of Neurosurgery Вопросы нейрохирургии, 1995; 2:23–25.|
|12. Lyubich LD, Lisyanyy MI. Sposib doslidzhennja alocytotoksychnoi’ aktyvnosti imunokompetentnyh klityn [The method of study of allocytotoxicity activity of immunocompetent cells]. Patent UA 75059, Ukrai’na. Opubl. 26.11.2012. Bjul. 22. – Patent UA 75059, Ukraine. Publ. 26.11.2012. Bull. 22.|
|13. Ghosh A, Bhattacharya M, Sarkar P, et al. T11 target structure exerts effector function by activating immune cells in CNS against glioma where cytokine modulation provide favorable microenvironment. Indian J. Exp. Biol. 2010; 48(9):879–888.
|14. Huang H, Hara A, Homma T, et al. Altered expression of immune defense genes in pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 2005; 64(10):891–901.
|15. Nano R, Capelli E, Facoetti A, et al. Immunobiological and experimental aspects of malignant astrocytoma. Anticancer Res. 2009; 29:2461–2466.
|16. Mehling M, Simon P, Mittelbronn M, et al. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol. 2007; 114(2):111–119.
|17. Kren L, Muckova K, Lzicarova E, et al. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity? J. Neuroimmunol. 2010; 220(1-2):131–135.
|18. Kren L, Slaby O, Muckova K, et al. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance. Neuropathology. 2011; 2:129–134.
|19. Klassen HJ, Imfeld KL, Kirov II, et al. Expression of cytokines by multipotent neural progenitor cells. Cytokine. 2003; 22(3-4):101–106.
|20. Liu J, Götherström C, Forsberg M, et al. Human neural stem/progenitor cells derived from embryonic stem cells and fetal nervous system present differences in immunogenicity and immunomodulatory potentials in vitro. Stem Cell Res. 2013; 10(3):325–337.
|21. Chen HC, Ma HI, Sytwu HK, et al. Neural stem cells secrete factors that promote auditory cell proliferation via a leukemia inhibitory factor signaling pathway. J. Neurosci. Res. 2010; 88(15):3308–3318.
|22. Lyubich LD. Ocinka vplyvu supernatantu progenitornyh nejroklityn shhura na ekspresiju antygeniv CD25 ta CD95 klitynamy gliom ljudyny [Assessing the impact of the supernatant progenitor neural cells rat on expression of CD25 and CD95 antigens of human gliomas]. Imunologija ta alergologija. Nauka i praktyka – Immunology and Allergology. Science and Practice, 2012; 2:31–36.|
Lyubich LD, Lisyany M. I. Effects of the neurogenic cells supernatant on the tumor-inducing ability of glioma 101.8 in rats. Cell and Organ Transplantology. 2015; 3(1):57-61. doi: 10.22494/COT.V3I1.17